Biotechonolgy and pharmaceutical
BioPharma Consulting?Services LLC
United States of America
Dr. Paul Fredlund has worked in clinical drug development designing and monitoring clinical trials in erectile dysfunction, diabetes, sepsis, Chron’s Disease, Non-Hodgkin’s Lymphoma and lung cancer. He has extensive experience drafting clinical study reports, preparing regulatory documents and evaluating potential in-licensing opportunities. He has a special interest in clinical drug safety (pharmacovigilance) and has served on several drug safety monitoring committees. In 2000 he joined ICOS Corporation and as Director; Clinical Research was actively involved in the clinical development and the successful worldwide registration of Cialis (tadalafil) for erectile dysfunction. In 2003/2004 Dr Fredlund was the Co-director of the Lilly/ICOS U.S. Affiliate Cialis™ Product Development Team responsible for the commercialization of Cialis and the design and implementation of Phase 4 Cialis clinical trials. Dr Fredlund graduated from Harvard College and Harvard Medical School. He completed his training with a residency in internal medicine at Harvard Medical School’s Peter Bent Brigham Hospital and a clinical fellowship in endocrinology and metabolism at the National Institutes of Health. He is board certified in internal medicine and endocrinology and has been a Clinical Professor of Medicine at the University of Washington School of Medicine.
His research interests are in Internal Medicine